Skip to main content
SearchLoginLogin or Signup

Review of "Characterization of an EG.5.1 Clinical Isolate In Vitro and In Vivo"

Reviewers: N Maness (Tulane University) | 📘📘📘📘📘

Published onJul 02, 2024
Review of "Characterization of an EG.5.1 Clinical Isolate In Vitro and In Vivo"
key-enterThis Pub is a Review of
Characterization of an EG.5.1 clinical isolate in vitro and in vivo
Characterization of an EG.5.1 clinical isolate in vitro and in vivo
Description

Abstract EG.5.1 is a subvariant of the SARS-CoV-2 Omicron XBB variant that is rapidly increasing in prevalence worldwide. EG.5.1 has additional substitutions in its spike protein (namely, Q52H and F456L) compared with XBB.1.5. However, the pathogenicity, transmissibility, and immune evasion properties of clinical isolates of EG.5.1 are largely unknown.In this study, we used wild-type Syrian hamsters to investigate the replicative ability, pathogenicity, and transmissibility of a clinical EG.5.1 isolate. Our data show that there are no obvious differences in growth ability and pathogenicity between EG.5.1 and XBB.1.5, and both EG.5.1 and XBB.1.5 are attenuated compared to a Delta variant isolate.We also found that EG.5.1 is transmitted more efficiently between hamsters compared with XBB.1.5. In addition, unlike XBB.1.5, we detected EG.5.1 virus in the lungs of four of six exposed hamsters, suggesting that the virus tropism of EG.5.1 is different from that of XBB.1.5 after airborne transmission.Finally, we assessed the neutralizing ability of plasma from convalescent individuals and found that the neutralizing activity against EG.5.1 was slightly, but significantly, lower than that against XBB.1.5 or XBB.1.9.2. This suggests that EG.5.1 effectively evades humoral immunity and that the amino acid differences in the S protein of EG.5.1 compared with that of XBB.1.5 or XBB.1.9.2 (i.e., Q52H, R158G, and F456L) alter the antigenicity of EG.5.1.Our data suggest that the increased transmissibility and altered antigenicity of EG.5.1 may be driving its increasing prevalence over XBB.1.5 in the human population.

To read the original manuscript, click the link above.

Summary of Reviews: The reviewer found the study strong, providing a timely assessment of the EG.5 SARS-CoV-2 variant. They highlighted findings that EG.5 is similar to XBB 1.5 in pathogenicity but may have enhanced lung infection efficiency and antibody escape. While suggesting additional comparisons for broader context, the reviewer considered this an important report, emphasizing EG.5's potential for slightly increased transmissibility and immune evasion without increased pathogenicity.

Reviewer 1 (Nicholas M…) | 📘📘📘📘📘

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below. 

Comments
0
comment
No comments here
Why not start the discussion?